Relationships of Coagulation Factor XIII Activity with Cell-Type and Stage of Non-Small Cell Lung Cancer
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Factor XIII (FXIII), a thrombin-activated plasma transglutaminase zymogen,is involved in cancer development and progression through a triggered coagulation pathway. The aim of this study was to examine whether FXIII activity levels differed in non-small cell lung cancer (NSCLC) patients according to histological types and TNM stage when compared with healthy subjects. Materials and Methods: Twenty-eight NSCLC patients and 28 normal controls who had been individually age-, gender-, body mass index-, smoking status-, and smoking amount-matched were enrolled: 13 adenocarcinomas, 11 squamous cell carcinomas, and four undifferentiated NSCLCs; four stage I, two stage II, 12 stage III, and 10 stage IV NSCLCs. FXIII activity was measured using fluorescence-based protein arrays. Results: The median FXIII activity level of the NSCLC group [24.2 Loewy U/mL, interquartile range (IQR) 14.9-40.4 Loewy U/mL] was significantly higher than that of the healthy group (17.5 Loewy U/mL, IQR 12.6-26.4 Loewy U/mL) (p=0.01). There were no differences in FXIII activity between adenocarcinoma (median 18.6 Loewy U/mL) and squamous cell carcinoma (median 28.7 Loewy U/mL). NSCLC stage significantly influenced FXIII activity (p=0.02). The FXIII activity of patients with stage III NSCLC (median 27.3 Loewy U/mL, IQR 19.3-40.5 Loewy U/mL) was significantly higher than those of patients with stage I or II (median 14.0 Loewy U/mL, IQR 13.1-23.1 Loewy U/mL, p=0.04). FXIII activity was negatively correlated with aPTT in NSCLC patients (r=-0.38, p=0.04). Conclusion: Patients with advanced-stage NSCLC exhibited higher coagulation FXIII activity than healthy controls and early-stage NSCLC patients.
Abstract
Purpose: Factor XIII (FXIII), a thrombin-activated plasma transglutaminase zymogen,is involved in cancer development and progression through a triggered coagulation pathway. The aim of this study was to examine whether FXIII activity levels differed in non-small cell lung cancer (NSCLC) patients according to histological types and TNM stage when compared with healthy subjects. Materials and Methods: Twenty-eight NSCLC patients and 28 normal controls who had been individually age-, gender-, body mass index-, smoking status-, and smoking amount-matched were enrolled: 13 adenocarcinomas, 11 squamous cell carcinomas, and four undifferentiated NSCLCs; four stage I, two stage II, 12 stage III, and 10 stage IV NSCLCs. FXIII activity was measured using fluorescence-based protein arrays. Results: The median FXIII activity level of the NSCLC group [24.2 Loewy U/mL, interquartile range (IQR) 14.9-40.4 Loewy U/mL] was significantly higher than that of the healthy group (17.5 Loewy U/mL, IQR 12.6-26.4 Loewy U/mL) (p=0.01). There were no differences in FXIII activity between adenocarcinoma (median 18.6 Loewy U/mL) and squamous cell carcinoma (median 28.7 Loewy U/mL). NSCLC stage significantly influenced FXIII activity (p=0.02). The FXIII activity of patients with stage III NSCLC (median 27.3 Loewy U/mL, IQR 19.3-40.5 Loewy U/mL) was significantly higher than those of patients with stage I or II (median 14.0 Loewy U/mL, IQR 13.1-23.1 Loewy U/mL, p=0.04). FXIII activity was negatively correlated with aPTT in NSCLC patients (r=-0.38, p=0.04). Conclusion: Patients with advanced-stage NSCLC exhibited higher coagulation FXIII activity than healthy controls and early-stage NSCLC patients.
참고문헌 (32)
- Kamangar F, "Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world", J Clin Oncol, 24, pp.2137~2150 (2006)
- Travis WD, "Lung cancer", Cancer, 75(1), pp.191~202 (1995)
- Pastorino U, "Lung cancer screening", Br J Cancer, 102, pp.1681~1686 (2010)
- Coate LE, "Molecular predictive and prognostic markers in non-small-cell lung cancer", Lancet Oncol, 10, pp.1001~1010 (2009)
- Montuenga LM, "Current challenges in lung cancer early detection biomarkers", Eur J Cancer, 45(1), pp.377~378 (2009)
- Wang X, "Ovarian cancer, the coagulation pathway, and inflammation", J Transl Med, 3, pp.25~ (2005)
- Kakkar AK, "Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS)", J Clin Oncol, 22, pp.1944~1948 (2004)
- Sampson MT, "Coagulation proteases and human cancer", Biochem Soc Trans, 30, pp.201~207 (2002)
- Camerer E, "Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis", Blood, 104, pp.397~401 (2004)
- Palumbo JS, "Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells", Blood, 96, pp.3302~3309 (2000)
- Dardik R, "Factor XIII (FXIII) and angiogenesis", J Thromb Haemost, 4, pp.19~25 (2006)
- Katona E, "Factor XIII in bronchoalveolar lavage fluid from children with chronic bronchoalveolar inflammation", J Thromb Haemost, 3, pp.1407~1413 (2005)
- Labat-Robert J, "Fibronectin in malignancy", Semin Cancer Biol, 12, pp.187~195 (2002)
- Palumbo JS, "Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice", Cancer Res, 62, pp.6966~6972 (2002)
- Jones JM, "Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer", Lung Cancer, 53, pp.97~101 (2006)
- Vairaktaris E, "Increased risk for oral cancer is associated with coagulation factor XIII but not with factor XII", Oncol Rep, 18, pp.1537~1543 (2007)
- An Y, "Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma", Dis Markers, 29, pp.11~20 (2010)
- Kiss F, "Leukemic lymphoblasts, a novel expression site of coagulation factor XIII subunit A", Thromb Haemost, 96, pp.176~182 (2006)
- Rami-Porta R, "The revised TNM staging system for lung cancer", Ann Thorac Cardiovasc Surg, 15, pp.4~9 (2009)
- Kim SJ, "The local prevalence of COPD by post-bronchodilator GOLD criteria in Korea", Int J Tuberc Lung Dis, 10, pp.1393~1398 (2006)
- Kwon MH, "Rapid determination of blood coagulation factor XIII activity using protein arrays for serodiagnosis of human plasma", Anal Chem, 83, pp.2317~2323 (2011)
- Palumbo JS, "Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function", J Thromb Haemost, 6, pp.812~819 (2008)
- Bobek V, "Antitumor and antimetastatic effect of warfarin and heparins", Biomed Pharmacother, 58, pp.213~219 (2004)
- Ferrigno D, "Prognostic significance of blood coagulation tests in lung cancer", Eur Respir J, 17, pp.667~673 (2001)
- Gouin-Thibault I, "Laboratory diagnosis of the thrombophilic state in cancer patients", Semin Thromb Hemost, 25, pp.167~172 (1999)
- Adány R, "Factor XIII subunit A as an intracellular transglutaminase", Cell Mol Life Sci, 60, pp.1049~1060 (2003)
- Lorand L, "Factor XIII and the clotting of fibrinogen: from basic research to medicine", J Thromb Haemost, 3, pp.1337~1348 (2005)
- Ichinose A, "Physiopathology and regulation of factor XIII", Thromb Haemost, 86, pp.57~65 (2001)
- Bárdos H, "Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx", Thromb Haemost, 80, pp.767~772 (1998)
- Roselli M, "Vascular endothelial growth factor (VEGF-A) plasma levels in non-small cell lung cancer: relationship with coagulation and platelet activation markers", Thromb Haemost, 89, pp.177~184 (2003)
- Jiang WG, "Expression of transglutaminases in human breast cancer and their possible clinical significance", Oncol Rep, 10, pp.2039~2044 (2003)
- Born P, "Reduced levels of coagulation factor XIII in patients with advanced tumor disease", Hepatogastroenterology, 47, pp.194~198 (2000)